Halozyme Therapeutics
$109.86Change from previous close: +2.73%Absolute change: +$2.92
At a glance
- Revenue growth
- +37.55%
- 2025 vs 2024
- Net income growth
- −28.64%
- 2025 vs 2024
- Net margin
- 22.7%
- 2024: 43.7%
Financial data
Amounts in millions of USD; per-share values in USD; shares in millions.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total revenue | 1,397 | 1,015 | 829 | 660 | — |
| Cost of revenue | 229 | 159 | 192 | 139 | — |
| Gross profit | — | 856 | 637 | 521 | 362 |
| Selling, general and administrative | 207 | 154 | 149 | 144 | — |
| Research and development | 81.5 | 79.0 | 76.4 | 66.6 | — |
| Operating income | 803 | 551 | 338 | 268 | — |
| EBIT | 485 | 575 | 367 | 266 | — |
| EBITDA | 573 | 657 | 452 | 316 | — |
| Interest expense | 18.1 | 18.1 | 18.8 | 16.9 | — |
| Pre-tax income | 467 | 557 | 348 | 249 | — |
| Income tax | 150 | 113 | 66.7 | 46.8 | — |
| Net income | 317 | 444 | 282 | 202 | — |
| Net income to common shareholders | 317 | 444 | 282 | 202 | — |
| Basic EPS | 2.64 | 3.50 | 2.13 | 1.48 | — |
| Diluted EPS | 2.56 | 3.43 | 2.10 | 1.44 | — |
| Average shares (basic) | 120 | 127 | 132 | 137 | — |
| Average shares (diluted) | 124 | 129 | 134 | 141 | — |